Home › Trials › NCT07172893

DermaBind TL for chronic diabetic foot and venous leg ulcers

A Non-Randomized Open Label Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of DermaBind TL, a Placental Membrane Allograft Intended for Use in the Management of Non-Healing Ulcers

PHASE4 · HealthTech Wound Care · NCT07172893

DermaBind TL, a placental allograft dressing, will be tried in adults with chronic non-healing diabetic foot ulcers or venous leg ulcers to see if wounds heal better over 12 weeks.

Quick facts

PhasePHASE4
Study typeInterventional
Enrollment150 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorHealthTech Wound Care (industry)
Drugs / interventionschemotherapy, radiation
Locations10 sites (DeLand, Florida and 9 other locations)
Trial IDNCT07172893 on ClinicalTrials.gov

What this trial studies

This is a prospective, multi-center, open-label, single-arm Phase 4 evaluation in which DermaBind TL will be applied to chronic non-healing diabetic foot ulcers or venous leg ulcers for a 12-week treatment period. Clinicians at three Florida sites will perform wound assessments and record outcomes including wound area preservation, infection rates, recurrence after end of study, number of grafts used, and treatment-emergent adverse events. The protocol uses each subject's historical wound data as context for outcomes rather than a randomized control group. Data will be summarized across subjects to characterize safety, tolerability, and effectiveness of the commercially available dressing.

Who should consider this trial

Good fit: Adults aged 18–80 with a single chronic non-healing diabetic foot ulcer (Wagner grade 1–2) or venous leg ulcer who have failed standard or conservative treatments and meet the study's diabetes stability and A1C criteria are ideal candidates.

Not a fit: Patients with wounds outside the included types, active severe infection or uncontrolled diabetes (A1C > 10%) or who cannot attend regular site visits are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, DermaBind TL could help protect chronic DFUs and VLUs and improve healing rates or reduce recurrence compared with prior outcomes for the same patients.

How similar studies have performed: Prior studies of placental/amnion-derived grafts for chronic wounds have reported positive healing and safety signals, though results vary by product and patient population.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* 1\. Be an adult between 18 and 80 years of age at the time of consent 2. Presence of a DFU, Wagner Grade 1 or 2 (see Appendix A for definitions) on the plantar, lateral or dorsal aspect of the foot, extending through the dermis provided it is below the medial aspect of the malleolus.

  3\. Subjects must have a diagnosis of Type I or Type II diabetes mellitus (DM) as defined by the American Diabetes Association
  1. for Type I DM, have been on a stable anti-diabetic treatment for at least 30 days before the baseline visit, or
  2. for Type II DM, must have been on a stable anti-diabetic medication for at least 30 days, or if diet-controlled only, must have been on stable diet-control for at least 6 months.

     4\. For Type I and Type II DM, A1C must be equal or \<10% in the last 30 days, or confirmed during the screening period (SV1 up to TV1) 5. Have a single target ulcer 6. If other DFU wounds are present on the same foot, they must be more than 2 cm distant from the index ulcer. \[NOTE: If two or more DFUs are present with the same grade on the same foot, the index ulcer is the largest ulcer and the only one evaluated in the study.\] 7. Have a wound with an area greater than 1cm2 and less than 25 cm2 and does not probe to bone 8. Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.

     9\. Index ulcer must be a DFU with a Wagner Grade of 1 or 2. 10. Have an absence of infection based on the Infectious Disease Society of America criteria and as evidenced by radiographic evidence (X-ray, CT or MRI scan) performed during the 14 Screening Period (SV1-TV1). Radiological evidence must be completed, resulted and confirmed by the treating study physician prior to application of study graft to index ulcer.

     11\. Have adequate circulation to the affected lower extremity confirmed during the screening period, defined as at least one of these criteria:

  <!-- -->

  1. TCOM ≥30 mmHg
  2. ABI between 0.7 and 1.3
  3. SPP \>30 mmHg
  4. As an alternative, Arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle on the extremity the index ulcer is located.

     12\. Have the ability to comply with protocol defined off-loading to the index ulcer and dressing change requirements 13. Patient is a non-tobacco user, including all forms of nicotine delivery (e.g., cigarettes, cigars, pipes, vaping devices, smokeless tobacco or nicotine patch) for a minimum of 4 weeks prior to the initial application of study graft. Verbal confirmation by subject is acceptable.

     14\. Have the ability to understand the requirements of the study and to give informed consent 15. Have a life expectancy of greater than 6 months 16. Have failed conservative wound care treatment of the index ulcer for at least of 4 weeks 17. Patient will not require negative pressure therapy to the index ulcer, antimicrobial dressings, hyperbaric oxygen therapy to the index ulcer during the study period.

     18\. Patient has not had radiation to the index ulcer site. 19. The index ulcer has a clean base, free of necrotic debris and infection at time of placement of treatment product.

     20\. The index ulcer has been off-loaded, per protocol requirements, with a CAM boot (Foot Defender®) or TCC for a minimum of 14 days (+3 days) following SV1.

     21\. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests at various timepoints during study participation.

     Exclusion Criteria:
* 1\. Pregnant or lactating 2. Less than 18 years of age 3. Has continued tobacco use 4. Have a wound that decreased in size ≥30% between the Screening and Treatment Visits 5. Wound is showing signs of healing and that improvement is likely to continue without treatment (increased granulation, epithelization, decrease in size ≥ 30% reduction in wound surface area).

  6\. Circulating hemoglobin A1c exceeding 10% within 30 days of the Screening Visit 7. Serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior to screening 8. The wound has been treated with biomedical or topical growth factors within the previous 30 days before the screening visit 9. Need for any additional concomitant dressing material other than the ones approved for this study 10. Osteomyelitis or bone infection of the affected foot as verified by x-ray or other radiographic modality within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision).

  11\. The inability to tolerate off-loading (a surgical shoe, removable cast walker or a total contact cast) 12. Have a known or suspected disease of the immune system 13. Have an active or untreated malignancy or active, uncontrolled connective tissue disease 14. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study.

  15\. At the index ulcer site, presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement 16. Had undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the baseline visit 17. Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening 18. Uncontrolled edema, lymphedema or venous HTN in the limb of the index ulcer 19. Undergone treatment to the index ulcer with a living skin equivalent within the last 4 weeks before screening 20. Undergone treatment to the index ulcer with a placental-derived allograft within the last 4 weeks before screening 21. Has the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated 22. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV1.

  23\. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes.

  24\. Subjects with a previous diagnosis of HIV or Hepatitis C, regardless of current status .

Where this trial is running

DeLand, Florida and 9 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Placental allograft, DermaBind TL

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.